1. Marksans Pharma
stock logo

100% Buy

Marksans Pharma Share Price

MARKSANS

₹162.85-₹1.30 (-0.79%) Past Year
₹159.05₹164.00
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • More

Company overview

About

arrow

Market cap

Market Cap Switch₹6,920 Cr

Open

₹161.50

Close

₹164.15

Circuit range

₹196.95 - ₹131.35

Day range

₹159.05 - ₹164.00

Year range

₹70.55 - ₹179.30

Volume

14,35,443

Avg. traded

₹162.15

Revenue (12m)

₹2,103 Cr

Marksans Pharma

Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.

The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.

Business operations

Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.

In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.

Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.

Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.

The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.

Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.

In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.

Financial Highlights

– Marksans Pharma’s revenue from operations for FY23 stood at ₹1,852 crore, up by 24.2% compared to ₹1,491 crore in FY22. – The net profit after tax for FY23 was ₹265.3 crore compared to ₹186.8 crore during the previous year. – In FY23, EBITDA increased to ₹339.3 crore from the previous year's ₹258.9 crore. – The company's earnings per share (EPS) stood at ₹6.4 in FY23 compared to ₹4.5 in the previous financial year.

Read more

Marksans Pharma Key indicators

arrow

52 week high

₹179.30

52 week low

₹70.55

P/E ratio

23.29

P/B ratio

3.77

ROE

11.41%

ROCE

14.27%

Dividend yield

0.31%

Debt/Equity ratio

EPS

2.27

Learn more

Investment checklist: (4/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

100%

Hold

0%

Sell

0%

This analysis is based on the reviews of 1 experts in the last 7 days

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

21.91%

Net profit margin

14.79%

ROE

11.41%

ROA

8.69%

ROCE

14.27%

Learn more

Marksans Pharma Shareholder returns

arrow

1 day

-0.06%

1 week

+1.14%

1 month

+9.76%

3 months

+0.52%

1 year

+127.04%

3 years

+193.12%

5 years

+533.78%

Revenue statement

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Cash flow

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Balance sheet

All values are in ₹ Crores (Cr)
arrow
Empty state

No data available at the moment

Marksans Pharma Share Price history

arrow
DayOpenCloseDay’s change
Wed, Apr 10 2024
₹165.50
₹164.15
-0.82%
Tue, Apr 9 2024
₹163.40
₹164.25
+0.52%
Mon, Apr 8 2024
₹162.80
₹162.05
-0.46%
Fri, Apr 5 2024
₹160.20
₹161.00
+0.50%
Thu, Apr 4 2024
₹163.35
₹161.35
-1.24%
Wed, Apr 3 2024
₹161.20
₹162.30
+0.68%
Tue, Apr 2 2024
₹160.00
₹161.00
+0.62%
Mon, Apr 1 2024
₹152.00
₹158.00
+3.80%

Shareholding info

arrow

Promoters (43.85%)

Mutual Funds (3.82%)

Retail and other (35.83%)

Foreign institutions-FII (15.55%)

Other domestic institutions (0.95%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹0.5/share

    Ex date 07 Jun 2023

    expand tab
  • Dividend • ₹0.25/share

    Ex date 19 Aug 2022

    expand tab

Learn more

Frequently asked questions